No Advantage Seen With Long-Term Oxygen Therapy for 24 Versus 15 Hours/Day
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 10, 2024 -- For patients starting long-term oxygen therapy for chronic, severe hypoxemia at rest, the risk for hospitalization or death within one year is comparable with long-term oxygen therapy for 24 or 15 hours per day, according to a study published online Sept. 10 in the New England Journal of Medicine to coincide with the European Respiratory Society Congress, held from Sept. 7 to 11 in Vienna.
Magnus Ekström, M.D., Ph.D., from Lund University in Sweden, and colleagues compared the risk for hospitalization or death at one year with long-term oxygen therapy for 24 versus 15 hours per day among patients who were starting oxygen therapy for chronic, severe hypoxemia at rest. Patients were randomly assigned to receive long-term oxygen therapy for 24 hours (117 patients) or 15 hours (124 patients) per day.
The researchers found that the risk for hospitalization or death within one year was not lower in the 24-hour versus the 15-hour group (mean rate, 124.7 and 124.5 events per 100 person-years, respectively; hazard ratio, 0.99; 95 percent confidence interval, 0.72 to 1.36; P = 0.007 for nonsuperiority). No substantial difference was seen between the groups in the incidence of hospitalization for any cause, death from any cause, or adverse events.
"This trial has direct clinical implications. The findings support that there is no clear disadvantage of supplemental oxygen use for 15 hours per day rather than 24 hours per day in terms of reducing the risk of hospitalization or death within one year," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Cardiorespiratory Effects of Smoke Fine Particulate Matter From Wildfires Can Persist for Months
THURSDAY, June 5, 2025 -- The cardiorespiratory effects of smoke fine particulate matter (PM2.5), a primary wildfire emission that can spike for months after a wildfire begins...
Multiple Environmental Exposures Jointly Contribute to Asthma Risk
WEDNESDAY, May 28, 2025 -- Air pollution, built environment, and ambient temperature jointly contribute to incident asthma risk, according to a study published online May 15 in...
Methotrexate Noninferior to Prednisone in Pulmonary Sarcoidosis
TUESDAY, May 20, 2025 -- For patients with pulmonary sarcoidosis, methotrexate is noninferior to prednisone with regard to the change from baseline to week 24 in the percentage of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.